SAN JOSE, Calif., July 28, 2020 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on the treatment and prevention of cancer and infectious diseases,
today announced that its prophylactic breast cancer vaccine is
making progress towards clinical trials.
Anixa and Cleveland Clinic intend to file the Investigational
New Drug (IND) Application with the US Food and Drug Administration
by the end of the current quarter. Despite government-mandated
laboratory closures, disruptions and constraints due to the
coronavirus pandemic, there has not been a significant delay in
this vaccine's development timeline.
This vaccine technology was invented by a research team from
Cleveland Clinic, led by Dr. Vincent
Tuohy, the Mort and Iris November Distinguished Chair in
Innovative Breast Cancer Research in the Department of Inflammation
and Immunity at Cleveland Clinic's Lerner Research Institute.
The underlying technology takes advantage of self-proteins that
have a function at certain times in life, but then become "retired"
and disappear from the body. One such protein, alpha-lactalbumin,
is expressed only in the mammary glands during lactation and then
disappears once lactation ceases. Dr. Tuohy discovered that
this protein is abnormally expressed again when a woman contracts
breast cancer, especially Triple Negative Breast Cancer (TNBC), the
most deadly form of this disease. Dr. Tuohy postulated that if
women could be immunized against this protein, after the age of
childbirth, the immune system could be trained to destroy the
cancer cells as they arise, thus making it difficult for the cancer
to gain critical mass. Early studies to test this theory
demonstrated highly significant prevention of breast cancer in
animal models.
"We are extremely excited to move forward with this
technology. At the current time, the bulk of the IND
application is completed. The main portion that remains to be
finished is the CMC section (Chemistry, Manufacture and Control),"
stated Dr. Amit Kumar, President and
CEO of Anixa Biosciences. "After completion of the IND, it will be
reviewed by our regulatory experts and committees and then filed
with the FDA. We have already had two pre-IND meetings with
the FDA as this is a novel vaccine technology."
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company developing a number of
programs addressing cancer and infectious disease. Anixa's
therapeutic portfolio includes a cancer immunotherapy program which
uses a novel type of CAR-T, known as chimeric endocrine receptor
T-cell (CER-T) technology, and a Covid-19 therapeutics program
focused on inhibiting certain viral protein function. The
company's vaccine portfolio consists of a technology focused on the
immunization against α-Lactalbumin to prevent triple negative
breast cancer (TNBC). Anixa continually examines emerging
technologies in complementary fields for further development and
commercialization. Additional information is available at
www.anixa.com.
Forward-Looking Statements: Statements
that are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We generally use
the words "believes," "expects," "intends," "plans," "anticipates,"
"likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We
undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You are
cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Tiberend Strategic Advisors, Inc.
Miriam Miller (Investors)
mmiller@tiberend.com
212-375-2694
Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-breast-cancer-vaccine-technology-nearing-fda-submission-301101036.html
SOURCE Anixa Biosciences, Inc.